Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in non-diabetic MAFLD patients
NCT05782972Phase 4Active, not recruiting
- Sponsor
- Buddhist Tzu Chi Medical Foundation
- Start
- Mar 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dapagliflozin in metabolic associated fatty liver disease (MAFLD), sponsored by Buddhist Tzu Chi Medical Foundation. Started Mar 2023; status: active, not recruiting.
02
Drugs
dapagliflozin
03
Conditions
metabolic associated fatty liver disease (MAFLD)
Beyond the preview
Go deeper on NCT05782972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05782972.